Text Size

Development of Method of Fructose Identification in Urine to Detect the Viral Infection

This study is currently recruiting participants.
Verified September 2012 by Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor:
Information provided by (Responsible Party):
Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01638312
First received: January 20, 2012
Last updated: September 28, 2012
Last verified: September 2012
History of Changes
  Purpose

The goal of this research is the attempt to implement a new research method based on modern electrochemistry successes, in particular the development of the polarographic method of fructose and fructose diphosphate identification and its implementation to detect the viral infection in early stage. There will be 30 samples from the HIV-infected patients and 30 samples from the heath controls. The study will collect 10ml urine and examined fructose and fructose-diphosphate using the polarographic method.


Condition
Human Immunodeficiency Virus

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Development of Fast and Simple Method of Fructose Identification in Urine to Detect the Viral Infection in Early Stage

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:

Biospecimen Retention:   None Retained

urine


Estimated Enrollment: 60
Study Start Date: June 2011
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
HIV infection patient

Detailed Description:

The goal of this research is the attempt to implement a new research method based on modern electrochemistry successes, in particular the development of the polarographic method of fructose and fructose diphosphate identification and its implementation to detect the viral infection in early stage.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

the person who has HIV infection

Criteria

Inclusion Criteria:

  • HIV infection

Exclusion Criteria:

  • who are in HARRT therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01638312

Contacts
Contact: JihJin Tsai, MD 886-7-3121101 ext 5677 jijits@cc.kmu.edu.tw

Locations
Taiwan
Tropical Medicine Center, Kaohsiung Medical University Chung-Ho Memorial Hospital Recruiting
Kaohsiung, Taiwan, 807
Contact: JihJin Tsai, MD     886-7-3121101 ext 5677     jijits@cc.kmu.edu.tw    
Contact: Ying Hui Wang, Master     886-7-3121101 ext 6358     try0506@gmail.com    
Sponsors and Collaborators
Kaohsiung Medical University Chung-Ho Memorial Hospital
Investigators
Principal Investigator: JihJin Tsai, MD The Medicines Company
  More Information

No publications provided

Responsible Party: Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier: NCT01638312     History of Changes
Other Study ID Numbers: KMUH-IRB-20110188
Study First Received: January 20, 2012
Last Updated: September 28, 2012
Health Authority: Taiwan: Department of Health

Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
HIV, fructose

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Virus Diseases
Lentivirus Infections
Retroviridae Infections
 RNA Virus Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013